# TSN084 Treating Patients With Advanced Malignant Tumors

> **NCT06386705** · PHASE1 · RECRUITING · sponsor: **Tyligand Bioscience (Shanghai) Limited** · enrollment: 114 (estimated)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** TSN084

## Key facts

- **NCT ID:** NCT06386705
- **Lead sponsor:** Tyligand Bioscience (Shanghai) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-20
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06386705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06386705, "TSN084 Treating Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06386705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*